Archived Immunization MMWRs 2021

2021 News Reports By Month

Readers can follow MMWR on Facebook and on twitter Twitter

January 7, 2022: Content on this page kept for historical reasons.

Current MMWRs Related to Immunization News

December 2021

QuickStats: Percentage of Children and Adolescents Aged 1–17 Years Who Received an Influenza Vaccine Within the Past 12 Months, by Health Insurance Coverage and Age Group — National Health Interview Survey, United States, 2019–2020 MMWR. 2021;70(5152);1785.
Throughout calendar years 2019–2020, 52.4% of children and adolescents aged 1–17 years received an influenza vaccine within the previous 12 months..
Jansen L, Tegomoh B, Lange K, Showalter K, Figliomeni J, Abdalhamid B, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021 MMWR. 2021;70(5152);1782–4.
The recent emergence of Omicron, which is now projected to be the dominant variant in the United States, reinforces the importance of vaccination, in coordination with other prevention strategies (e.g., masking and physical distancing), to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging…
Nemoto N, Dhillon S, Fink S, Holman EJ, Cope AK, Dinh T, et al. Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools — Lake County, Illinois, August 9–October 29, 2021 MMWR. 2021;70(5152);1778–81.
Although vaccination remains the leading recommendation to protect against COVID-19, TTS allows close contacts to remain in the classroom as an alternative to home quarantine…
Harris-McCoy K, Lee VC, Munna C, Kim AA. Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021 MMWR. 2021;70(5152);1773–7.
TTS does not appear to increase transmission risk in public schools and might greatly reduce loss of in-person school days…
Wanga V, Gerdes ME, Shi DS, Choudhary R, Dulski TM, Hsu S, et al. Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021 MMWR. 2021;70(5152);1766–72.
COVID-19 vaccination and other prevention strategies are important to protect children from COVID-19, particularly children with obesity and other underlying health conditions…
Lutrick K, Rivers P, Yoo YM, Grant L, Hollister J, Jovel K, et al. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021 MMWR. 2021;70(5152);1761–5.
In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection…
Hause AM, Baggs J, Marquez P, Myers TR, Gee J, Su JR, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 MMWR. 2021;70(5152);1755–60.
This report provides preliminary safety findings from VAERS and v-safe data collected during the administration of approximately 8 million doses of Pfizer-BioNTech COVID-19 vaccine to children aged 5–11 years…
Dulski TM, DeLong M, Garner K, Patil N, Cima MJ, Rothfeldt L, et al. Notes from the Field: COVID-19–Associated Mucormycosis — Arkansas, July–September 2021 MMWR. 2021;70(50);1750–1.
Maintenance of glycemic control in patients with diabetes, guideline-based use of corticosteroids for COVID-19 treatment, and vaccination against COVID-19 should be encouraged…
Mejía-Santos H, Montoya S, Chacón-Fuentes R, Zielinski-Gutierrez E, Lopez B, Ning MF, et al. Notes from the Field: Mucormycosis Cases During the COVID-19 Pandemic — Honduras, May–September 2021 MMWR. 2021;70(50);1747–9.
Prevention of COVID-19 through vaccination, maintenance of glycemic control in patients with diabetes, and judicious use of steroids for COVID-19 treatment might help decrease the risk for mucormycosis associated with COVID-19…
Fast HE, Zell E, Murthy BP, Murthy N, Meng L, Scharf LG, et al. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 MMWR. 2021;70(50);1735-9.
Strategic efforts are needed to encourage eligible persons aged ≥18 years, especially those aged ≥65 years and those who are immunocompromised, to receive a booster and/or additional primary dose to ensure maximal protection against COVID-19…
CDC COVID-19 Response Team. SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021 MMWR. 2021;70(50);1731-4.
This report summarizes U.S. surveillance for SARS-CoV-2 variants, characteristics of the initial persons investigated with COVID-19 attributed to the Omicron variant and public health measures implemented to slow the spread of Omicron in the United States….
Nguyen KH, Yankey D, Lu P, Kriss JL, Brewer NT, Razzaghi H, et al. Report of Health Care Provider Recommendation for COVID-19 Vaccination Among Adults, by Recipient COVID-19 Vaccination Status and Attitudes — United States, April–September 2021 MMWR. 2021;70(50);1723–30.
A health care provider recommendation for COVID-19 vaccines at every visit could increase coverage and confidence in vaccines, particularly among groups with lower COVID-19 vaccination coverage, including younger adults, racial/ethnic minorities, and rural residents…
Paz-Bailey G, Adams L, Wong JM, Poehling KA, Chen WH, McNally V, et al. Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021 MMWR. 2021; 70(RR-6);1–16.
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the Dengvaxia vaccine in the United States…
Delahoy MJ, Mortenson L, Bauman L, Marquez J, Bagdasarian N, Coyle J, et al. Influenza A(H3N2) Outbreak on a University Campus — Michigan, October–November 2021 MMWR. 2021;70(49);1712-4.
The findings of this investigation highlight the importance of increasing vigilance for influenza disease this winter, as indicated in CDC’s Health Alert Network Health Advisory issued on November 24, 2021…
Bajema KL, Dahl RM, Evener SL, Prill MM, Rodriguez-Barradas MC, Marconi VC, et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021 MMWR. 2021;70(49);1700–5.
These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19…
Alleman MM, Jorba J, Henderson E, Diop OM, Shaukat S, Traoré MA, et al. Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2020–June 2021 MMWR. 2021;70(49);1691–9.
This report updates that of July 2019–February 2020 to describe global cVDPV outbreaks during January 2020–June 2021 (as of November 9, 2021)…
Montgomery MP, Meehan AA, Cooper A, Toews K, Ghinai I, Schroeter MK, et al. Notes from the Field: COVID-19 Vaccination Coverage Among Persons Experiencing Homelessness — Six U.S. Jurisdictions, December 2020–August 2021 MMWR. 2021;70(48);1676–8.
Through conversations with public health and housing assistance partners, CDC identified six* urban public health jurisdictions with data on vaccination coverage among persons experiencing homelessness…

November 2021

Kasehagen L, Byers P, Taylor K, Kittle T, Roberts C, Collier C, et al. COVID-19–Associated Deaths After SARS-CoV-2 Infection During Pregnancy — Mississippi, March 1, 2020–October 6, 2021 MMWR. 2021;70(47);1646–8.
This report describes 15 COVID-19–associated deaths after infection with SARS-CoV-2 (the virus that causes COVID-19) during pregnancy in Mississippi during March 1, 2020–October 6, 2021…
DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization — United States, March 2020–September 2021 MMWR. 2021;70(47);1640–5.
Implementing evidence-based COVID-19 prevention strategies, including vaccination before or during pregnancy, is critical to reduce the impact of COVID-19 on stillbirths…
Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021 MMWR. 2021;70(45);1579–83).
The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5–11 years, and benefits outweigh risks for vaccination…
Roman PC, Kirtland K, Zell ER, Jones-Jack N, Shaw L, Shrader L, et al. Influenza Vaccinations During the COVID-19 Pandemic — 11 U.S. Jurisdictions, September–December 2020 MMWR. 2021;70(45);1575–8.
Continued strategic efforts are needed to ensure high influenza vaccination coverage among all eligible persons aged ≥6 months, especially children aged ≤4 years…
Dixon MG, Ferrari M, Antoni S, Li X, Portnoy A, Lambert B, et al. Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 MMWR. 2021;70(45);1563–9.
This report describes progress toward World Health Assembly milestones and measles elimination objectives during 2000–2020 and updates a previous report…
Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021 MMWR. 2021;70(44);1553–9.
Immunocompromised persons benefit from COVID-19 mRNA vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons…
Mbaeyi S, Oliver SE, Collins JP, Godfrey M, Goswami ND, Hadler SC, et al. The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 MMWR. 2021;70(44);1545–52.
Health care professionals play a critical role in COVID-19 vaccination efforts, including for primary, additional primary, and booster vaccination, particularly to protect patients who are at increased risk for severe illness and death…
Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 MMWR. 2021;70(44);1539–44.
This report focused on the early protection from infection-induced and vaccine-induced immunity, though it is possible that estimates could be affected by time…

Top of Page

October 2021

Xu S, Huang R, Sy LS, Glenn SC, Ryan DS, Morrissette K, et al. COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021 MMWR. 2021;70(43);1520–4.
During December 2020–July 2021, COVID-19 vaccine recipients had lower rates of non–COVID-19 mortality than did unvaccinated persons after adjusting for age, sex, race and ethnicity, and study site…
Taylor CA, Patel K, Pham H, Whitaker M, Anglin O, Kambhampati AK, et al. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021 MMWR. 2021;70(43);1513–9.
The proportion of hospitalized unvaccinated COVID-19 patients aged 18–49 years significantly increased during the Delta period…
Muhoza P, Danovaro-Holliday MC, Diallo MS, Murphy P, Sodha SV, Requejo JH, et al. Routine Vaccination Coverage — Worldwide, 2020 MMWR. 2021;70(43);1495–500.
This report, which updates a previous report, presents global, regional, and national vaccination coverage estimates and trends as of 2020…
Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 MMWR. 2021;70(42);1483–8.
This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years…
Hill HA, Yankey D, Elam-Evans LD, Singleton JA, Sterrett N. Vaccination Coverage by Age 24 Months Among Children Born in 2017 and 2018 — National Immunization Survey-Child, United States, 2018–2020 MMWR. 2021;70(41);1435–40.
Persistent disparities in vaccination coverage by health insurance status, race and ethnicity, and poverty status indicate that improvement is needed to achieve equity in the national childhood vaccination program…
Tonzel JL, Sokol T. COVID-19 Outbreaks at Youth Summer Camps — Louisiana, June–July 2021 MMWR. 2021;70(40);1425–6.
This report describes COVID-19 outbreaks in Louisiana youth summer camps as the Delta variant became the predominant lineage during June–July 2021…
Braun KVN, Drexler M, Rozenfeld RA, Deener-Agus E, Greenstein R, Agus M, et al. Multicomponent Strategies to Prevent SARS-CoV-2 Transmission — Nine Overnight Youth Summer Camps, United States, June–August 2021 MMWR. 2021;70(40);1420–4.
Implementation of high vaccination coverage coupled with multiple prevention strategies is critical to averting COVID-19 outbreaks in congregate settings, including overnight camps…
Malden DE, Bruxvoort KJ, Tseng HF, Ackerson B, Choi SK, Florea A, et al. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021 MMWR. 2021;70(40);1415–9.
These findings reinforce the importance of continued monitoring of SARS-CoV-2 variants and implementing multicomponent COVID-19 prevention strategies, particularly during the current period in which Delta is the predominant circulating variant in the United States…

Top of Page

September 2021

Mbaeyi C, Baig S, Khan Z, Young H, Kader M, Jorba J, et al. Progress Toward Poliomyelitis Eradication — Pakistan, January 2020–July 2021 MMWR. 2021;70(39);1359–64.
This report describes Pakistan’s progress toward polio eradication during January 2020–July 2021 and updates previous reports…
Hause AM, Baggs J, Gee J, Marquez P, Myers TR, Shimabukuro TT, et al. Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021 MMWR. 2021;70(39);1379–84.
Voluntary reports to v-safe found no unexpected patterns of adverse reactions after an additional dose of COVID-19 vaccine…
Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021 MMWR. 2021;70(38);1349–54.
Even with high vaccination rates, maintaining multicomponent prevention strategies (e.g., testing and masking for all persons and prompt medical isolation and quarantine for incarcerated persons) remains critical to limiting SARS-CoV-2 transmission in congregate settings where physical distancing is challenging…
Dooling K, Gargano JW, Moulia D, Wallace M, Rosenblum HG, Blain AE, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 MMWR. 2021;70(38);1344–8.
Continued use of the Pfizer-BioNTech COVID-19 vaccine, now fully approved by the FDA in persons aged ≥16 years, is recommended based on increased certainty that its benefits (prevention of asymptomatic infection, COVID-19, and associated hospitalization and death) outweigh vaccine-associated risks…
Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 MMWR. 2021;70(38);1337–43.
Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization…
Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 MMWR. 2021;70(37);1306–11.
These findings support the implementation of multicomponent approach to controlling the pandemic, centered on vaccination, as well as other prevention strategies such as masking and physical distancing…
Correction and Republication: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 MMWR. 2021;70(37);1305.
MMWR has republished the report, which includes the original report with clearly marked corrections in supplementary materials…
Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC, Marconi VC, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021 MMWR. 2021;70(37);1294–9.
These findings show that the COVID-19 mRNA vaccines remain highly effective for preventing COVID-19–associated hospitalization in this older, racially diverse population of predominantly male U.S. veterans, including during periods of widespread circulation of the SARS-CoV-2 Delta variant…
Grannis SJ, Rowley EA, Ong TC, Stenehjem E, Klein NP, DeSilva MB, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021 MMWR. 2021;70(37);1291–3.
These findings reaffirm the high protection of COVID-19 vaccines against moderate and severe COVID-19 resulting in ED, UC, and hospital visits and underscore the importance of full COVID-19 vaccination and continued benefits of COVID-19 vaccination during Delta variant predominance…
Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021 MMWR. 2021;70(37);1284–90.
Getting vaccinated protects against severe illness from COVID-19, including the Delta variant…
Quint JJ, Van Dyke ME, Maeda H, Worthington JK, Dela Cruz MR, Kaholokula JK, et al. Disaggregating Data to Measure Racial Disparities in COVID-19 Outcomes and Guide Community Response — Hawaii, March 1, 2020–February 28, 2021 MMWR. 2021;70(37);1267–73.
Disaggregating race data can aid in identifying racial disparities among specific subpopulations and highlights the importance of partnering with communities to develop culturally responsive outreach teams and tailored public health interventions and vaccination campaigns to more effectively address health disparities…
Delahoy MJ, Ujamaa D, Whitaker M, O’Halloran A, Anglin O, Burns E, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021 MMWR. 2021;70(36);1255–60.
Preventive measures to reduce transmission and severe outcomes in children and adolescents are critical, including vaccination, universal masking in schools, and masking by persons aged ≥2 years in other indoor public spaces and child care centers…
Siegel DA, Reses HE, Cool AJ, Shapiro CN, Hsu J, Boehmer TK, et al. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0–17 Years — United States, August 2020–August 2021 MMWR. 2021;70(36);1249–54.
Community vaccination, in coordination with testing strategies and other prevention measures, is critical to protecting pediatric populations from SARS-CoV-2 infection and severe COVID-19…
Rebmann T, Loux TM, Arnold LD, Charney R, Horton D, Gomel A. SARS-CoV-2 Transmission to Masked and Unmasked Close Contacts of University Students with COVID-19 — St. Louis, Missouri, January–May 2021 MMWR. 2021;70(36);1245–8.
CDC recommends that universal masking be adopted in indoor spaces for vaccinated and unvaccinated persons in areas with substantial or high transmission rates and that masks should be worn in indoor spaces in areas without substantial or high transmission rates if you are not fully vaccinated…
Wanga V, Chevinsky JR, Dimitrov LV, Gerdes ME, Whitfield GP, Bonacci RA, et al. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020–April 2021 MMWR. 2021;70(36);1235–41.
These findings can aid efforts to address post-COVID conditions and messaging on potential benefits of vaccination…
Pingali P, Yankey D, Elam-Evans LD, Markowitz LE, Williams CL, Fredua B, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2020 MMWR. 2021;70(35);1183-90.
This report provides vaccination coverage estimates for 20,163 adolescents aged 13–17 years…
Doyle K, Teran RA, Reefhuis J, Kerins JL, Qiu X, Green SJ, et al. Multiple Variants of SARS-CoV-2 in a University Outbreak After Spring Break — Chicago, Illinois, March–May 2021 MMWR. 2021;70(35);1195-200.
To mitigate SARS-CoV-2 transmission, colleges and universities can encourage COVID-19 vaccination; discourage unvaccinated students from traveling, including during university breaks; implement serial screening after university breaks; test based on community transmission; and encourage masking…
Murthy BP, Zell E, Saelee R, Murthy N, Meng L, Meador S, et al. COVID-19 Vaccination Coverage Among Adolescents Aged 12–17 Years — United States, December 14, 2020–July 31, 2021 MMWR. 2021;70(35);1206-13.
Improving adolescent COVID-19 vaccination coverage is crucial to reduce COVID-19–associated morbidity and mortality among adolescents and can help facilitate safer reopening of schools for in-person learning…
Matthias J, Patrick S, Wiringa A, Pullman A, Hinton S, Campos J, et al. Epidemiologically Linked COVID-19 Outbreaks at a Youth Camp and Men’s Conference — Illinois, June–July 2021 MMWR. 2021;70(35);1223-7.
This investigation underscores the impact of secondary SARS-CoV-2 transmission during large events such as camps and conferences when COVID-19 prevention strategies, including vaccination, masking, physical distancing, and screening testing, are not implemented…
Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021 MMWR. 2021;70(35);1228-32.
These findings underscore the importance of implementing evidence-based COVID-19 prevention strategies, including vaccination, to reduce the public health impact of COVID-19 and its associated complications…
Lam-Hine T, McCurdy SA, Santora L, Duncan L, Corbett-Detig R, Kapusinszky B, et al. Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School — Marin County, California, May–June 2021 MMWR. 2021;70(35);1214-9.
Vaccines are effective against the Delta variant, but transmission risk remains elevated among unvaccinated persons in schools…

Top of Page

August 2021

Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, et al. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021 MMWR. 2021;70(34);1170–6.
Efforts to enhance COVID-19 vaccination coverage, in coordination with other prevention strategies, are critical to preventing COVID-19–related hospitalizations and deaths…
Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, et al. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021 MMWR. 2021;70(34);1167-9.
This report updates vaccine effectiveness (VE) estimates including all COVID-19 vaccines available through August 14, 2021, and examines whether VE differs for adults with increasing time since completion of all recommended vaccine doses…
Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 MMWR. 2021;70(34);1163-6.
Multicomponent COVID-19 prevention strategies, including vaccination of nursing home staff members, residents, and visitors, are critical…
Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 MMWR. 2021;70(34);1156-62.
mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; ongoing monitoring is needed as new SARS-CoV-2 variants emerge…
Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 MMWR. 2021;70(34);1150-5.
These findings support the implementation of multicomponent approach to controlling the pandemic, centered on vaccination, as well as other prevention strategies such as masking and physical distancing…
Bigouette JP, Wilkinson AL, Tallis G, Burns CC, Wassilak SG, Vertefeuille JF. Progress Toward Polio Eradication — Worldwide, January 2019–June 2021 MMWR. 2021;70(34);1129–35.
This report summarizes progress toward global polio eradication during January 1, 2019–June 30, 2021 and updates previous reports…
Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season MMWR. 2021;70(RR-5);1-28.
This report updates the 2020–21 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2020;69[No. RR-8])…
Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 MMWR. 2021;70(32);1094-9.
Continued COVID-19 vaccination will prevent COVID-19 morbidity and mortality far exceeding GBS, TTS, and myocarditis cases expected. Information about rare adverse events should be disseminated to providers, vaccine recipients, and the public…
Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021 MMWR. 2021;70(32);1088-93.
Efforts to increase vaccination coverage are critical to reducing the risk for COVID-19–related hospitalization, particularly in older adults…
Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, et al. Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021 MMWR. 2021;70(32);1084-7.
Vaccination is critical for preventing infection, serious illness, and death associated with SARS-CoV-2 infection (including the Delta variant)…
Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 MMWR. 2021;70(32);1081-3.
This report details the findings of a case-control evaluation of the association between vaccination and SARS-CoV-2 reinfection in Kentucky during May–June 2021 among persons previously infected with SARS-CoV-2 in 2020…
Yoon P, Hall J, Fuld J, Mattocks SL, Lyons BC, Bhatkoti R. Alternative Methods for Grouping Race and Ethnicity to Monitor COVID-19 Outcomes and Vaccination Coverage MMWR. 2021;70(32);1075–80.
Multiple data sources are needed to monitor disparities and continued efforts are needed to strengthen the reporting of these data, consistent with CDC’s Data Modernization Initiative…
Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021 MMWR. 2021;70(31);1053-8.
The Advisory Committee on Immunization Practices conducted a risk-benefit assessment and continues to recommend the Pfizer-BioNTech COVID-19 vaccine for all persons aged ≥12 years…
Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 MMWR. 2021;70(31);1059-62.
Jurisdictions might consider expanded prevention strategies, including universal masking in indoor public settings, particularly for large public gatherings that include travelers from many areas with differing levels of SARS-CoV-2 transmission…

Top of Page

July 2021

Christie A, Brooks JT, Hicks LA, Sauber-Schatz EK, Yoder JS, Honein MA, et al. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage MMWR. 2021;70(30);1044–7.
Although increasing COVID-19 vaccination coverage remains the most effective means to achieve control of the pandemic, additional layered prevention strategies will be needed in the short-term to minimize preventable morbidity and mortality…
Rubin D, Eisen M, Collins S, Pennington JW, Wang X, Coffin S. SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program — Philadelphia County, Pennsylvania, March 21–April 23, 2021 MMWR. 2021;70(30);1040–3.
Efforts to promote COVID-19 vaccination among school staff members before the upcoming 2021–22 school year will be foundational to ensure a safe learning environment…
Lee JT, Althomsons SP, Wu H, Budnitz DS, Kalayil EJ, Lindley MC, et al. Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network — United States, March 2021 MMWR. 2021;70(30);1036–9.
Additional efforts to improve LTCF immunization practices, build confidence in COVID-19 vaccines, and promote COVID-19 vaccination are needed…
Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. Progress Toward Hepatitis B Control — World Health Organization European Region, 2016–2019 MMWR. 2021;70(30);1029–35.
This report describes the progress made toward hepatitis B control in EUR during 2016–2019…
Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021 MMWR. 2021;70(28);1004–7.
Multicomponent prevention strategies including vaccination remain important to reduce the spread of SARS-CoV-2 among persons participating in indoor sports and their contacts…
Scherer AM, Gedlinske AM, Parker AM, Gidengil CA, Askelson NM, Petersen CA, et al. Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents — United States, April 15–23, 2021 MMWR. 2021;70(28);997–1003.
Efforts focusing on effectively communicating the benefits and safety of COVID-19 vaccination for adolescents to the public could help increase adolescent COVID-19 vaccine confidence and vaccination coverage…
Wong CA, Dowler S, Moore AF, PharmD, Sosne EF, Young H, et al. COVID-19 Vaccine Administration, by Race and Ethnicity — North Carolina, December 14, 2020–April 6, 2021 MMWR. 2021;70(28);991–6.
To promote equitable vaccination coverage, public health officials could consider using U.S. Census tract-level mapping to guide vaccine allocation, promote shared accountability for equitable distribution of vaccines with providers through data sharing, and facilitate community partnerships to support vaccine access…
Pingali C, Meghani M, Razzaghi H, Lamias MJ, Weintraub E, Kenigsberg TA, et al. COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021 MMWR. 2021;70(28);985–90.
Continued monitoring of vaccination coverage and efforts to improve equity in vaccination coverage are critical, especially among populations disproportionately affected by COVID-19…
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 MMWR. 2021;70(26);977–82.
On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination…

Top of Page

June 2021

Baack BN, Abad N, Yankey D, Kahn KE, Razzaghi H, Brookmeyer K, et al. COVID-19 Vaccination Coverage and Intent Among Adults Aged 18–39 Years — United States, March–May 2021 MMWR. 2021;70(25);928–33.
Addressing concerns about COVID-19 vaccine safety and efficacy and emphasizing the role of vaccination in protecting family and friends and resuming social activities might help increase coverage…
Diesel J, Sterrett N, Dasgupta S, Kriss JL, Barry V, Esschert KV, et al. COVID-19 Vaccination Coverage Among Adults — United States, December 14, 2020–May 22, 2021 MMWR. 2021;70(25);922–7.
Efforts to improve vaccination coverage are needed, especially among younger adults, to reduce COVID-19 cases, hospitalizations, and deaths…
Razzaghi H, Meghani M, Pingali C, Crane B, Naleway A, Weintraub E, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021 MMWR. 2021;70(24);895–9.
Improving outreach to and engagement with health care providers and pregnant women, especially those who are younger and from racial and ethnic minority groups, could increase vaccine confidence and thus coverage of COVID-19 vaccination in this population…
Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021 MMWR. 2021;70(23);858–64.
The greater decline in COVID-19 morbidity and mortality in older adults, the age group with the highest vaccination rates, demonstrates the potential impact of increasing population-level vaccination coverage…
Havers FP, Whitaker M, Self JL, Chai SJ, Kirley PD, Alden NB, et al. Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021 MMWR. 2021;70(23);851–7.
Recent increased hospitalization rates in spring 2021 and potential for severe disease reinforce the importance of continued COVID-19 prevention measures, including vaccination and correct and consistent mask wearing among persons not fully vaccinated or when required…
Murthy BP, Zell E, MStat, Kirtland K, Jones-Jack N, Harris L, Sprague C, et al. Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations — 10 U.S. Jurisdictions, March–September 2020 MMWR. 2021;70(23);840–5.
To prevent outbreaks of vaccine-preventable diseases, health care providers should assess the vaccination status of all pediatric patients, including adolescents, and contact those who are behind schedule to ensure that all children and adolescents are fully vaccinated…
O’Connor P, Yankovic D, Zimmerman L, Ben Mamou M, Reef S. Progress Toward Rubella Elimination — World Health Organization European Region, 2005–2019 MMWR. 2021;70(23);833–9.
This report updates a previous report and describes progress toward rubella and CRS elimination in EUR during 2005–2019…
Barry V, Dasgupta S, Weller DL, Kriss JL, Cadwell BL, Rose C, et al. Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity — United States, December 14, 2020–May 1, 2021 MMWR. 2021;70(22);818–24.
Disparities in county-level vaccination coverage by social vulnerability have increased as vaccine eligibility has expanded, especially in large fringe metropolitan (areas surrounding large cities, e.g., suburban) and nonmetropolitan counties…

Top of Page

May 2021

CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021 MMWR. 2021;70(21);792–3.
Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended doses of an FDA-authorized COVID-19 vaccine) will develop symptomatic or asymptomatic infections with SARS-CoV-2, the virus that causes COVID-19…
Murthy BP, Sterrett N, Weller D, Zell E, MStat, Reynolds L, Toblin RL, et al. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–April 10, 2021 MMWR. 2021;70(20);759–64.
Disparities in COVID-19 vaccination access and coverage between urban and rural communities can hinder progress toward ending the pandemic…
Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 MMWR. 2021;70(20);753–8.
The mRNA vaccines are highly effective at preventing symptomatic COVID-19 among U.S. HCP. High vaccination coverage among HCP and the general population is critical to prevent COVID-19 in the United States…
Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021 MMWR. 2021;70(20);749–52.
The Pfizer-BioNTech COVID-19 vaccine is the first COVID-19 vaccine approved for use in adolescents and has high efficacy against symptomatic COVID-19. Vaccination will be important to protect adolescents against symptomatic COVID-19 disease and to reduce community transmission of SARS-CoV-2…
Whiteman A, Wang A, McCain K, Gunnels B, Toblin R, Lee JT, et al. Demographic and Social Factors Associated with COVID-19 Vaccination Initiation Among Adults Aged ≥65 Years — United States, December 14, 2020–April 10, 2021 MMWR. 2021;70(19);725–30.
Monitoring demographic and social factors affecting COVID-19 vaccine access for older adults and prioritizing efforts to ensure equitable access to COVID-19 vaccine are needed to ensure high coverage among this group…
Borchering RK, Viboud C, Howerton E, Smith CP, Truelove S, Runge MC, et al. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios — United States, April–September 2021 MMWR. 2021;70(19);719–24.
High vaccination coverage and compliance with NPIs are essential to control COVID-19 and prevent surges in hospitalizations and deaths in the coming months…
Lu P, Hung M, Srivastav A, Grohskopf LA, Kobayashi M, Harris AM, et al. Surveillance of Vaccination Coverage Among Adult Populations — United States, 2018 MMWR. 2021;ss70(3);1–26.
This report summarizes data on vaccination coverage for U.S. adults aged ≥19 years using data from the 2017 and 2018 National Health Interview Survey (NHIS), an ongoing in-person survey of eligible civilian noninstitutionalized adults…
Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021 MMWR. 2021;70(18);685–8.
Vaccine providers should be aware of anxiety-related events after vaccination and observe all COVID-19 vaccine recipients for any adverse reactions for at least 15 minutes after vaccine administration…
Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 MMWR. 2021;70(18);680–4.
This report summarizes adverse events among Janssen vaccine recipients, including non-CVST cases of thrombosis with thrombocytopenia syndrome (TTS), reported to the Vaccine Adverse Events Reporting System (VAERS), a passive surveillance system, and through v-safe, an active monitoring system…
Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 MMWR. 2021;70(18);674–9.
SARS-CoV-2 vaccines significantly reduce the risk for COVID-19–associated hospitalization in older adults and, in turn, might lead to commensurate reductions in post-COVID conditions and deaths…

Top of Page

April 2021

MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 MMWR. 2021;70(17);651–6.
On April 23, the Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18–49 years…
Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021 MMWR. 2021;70(17);639–43.
Vaccination of SNF residents and HCP is essential to reduce the risk for symptomatic COVID-19, as is continued focus on infection prevention and control practices…
Teran RA, Walblay KA, Shane EL, Xydis S, Gretsch S, Gagner A, et al. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members — Chicago, Illinois, December 2020–March 2021 MMWR. 2021;70(17);632–8.
SNFs should prioritize vaccination and follow recommended COVID-19 infection prevention and control practices, including following work restrictions, isolation, quarantine, testing of residents and staff members, and use of personal protective equipment…
Salman O, Topf K, Chandler R, Conklin L. Progress in Immunization Safety Monitoring — Worldwide, 2010–2019 MMWR. 2021;70(15);547–51.
This report describes global progress toward meeting World Health Organization (WHO) indicators on minimal country capacity for vaccine safety surveillance and coordination of AEFI reporting between countries’ EPI and NRAs. In 2019, among 194 countries, 129 (66.5%) reported having an operational national AEFI causality review committee, compared with 94 (48.5%) in 2010…

Top of Page

March 2021

Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 MMWR. 2021;70(13);495–500.
Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions…
Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, et al. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities — Four States, September–December 2020 MMWR. 2021;70(13);473–7.
This report underscores the urgent need for interventions that are culturally relevant and appropriate for various health literacy levels to increase vaccine confidence among incarcerated or detained persons…
Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018 MMWR. 2021;70(12);415–20.
This report adds to the robust data on the impact of the national HPV vaccination program, including herd effects…
Hughes MM, Wang A, Grossman MK, Pun E, Whiteman A, Deng L, et al. County-Level COVID-19 Vaccination Coverage and Social Vulnerability — United States, December 14, 2020–March 1, 2021 MMWR. 2021;70(12);431–6.
Continued monitoring of vaccination coverage by social vulnerability metrics is critical for developing tailored, local vaccine administration and outreach efforts to reduce COVID-19 vaccination inequities…
Britton A, Slifka KMJ, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021 MMWR. 2021;70(11);396–401.
Even with partial vaccination, Pfizer-BioNTech COVID-19 vaccine provides protection to SNF residents…
Kriss JL, Reynolds LE, Wang A, Stokley S, Cole MM, Harris LQ, et al. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 MMWR. 2021;70(11);389–95.
Identifying and addressing possible barriers to completing the COVID-19 vaccination series can help ensure equitable coverage across communities and optimal health benefits for recipients…
Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 MMWR. 2021;70(9);329–32.
The Janssen COVID-19 vaccine has high efficacy against COVID-19–associated hospitalization and death…

Top of Page

February 2021

Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021 MMWR. 2021;70(9);326–8.
These findings provide preliminary evidence of the effectiveness of vaccines in preventing severe cases of COVID-19 at the national level in Israel…
Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, Nair N, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 MMWR. 2021;70(8);283–8.
Monitoring, conducted as part of the U.S. vaccination program, indicates reassuring safety profiles for COVID-19 vaccines…
Batdorf SJ, Hofmeister MG, Surtees TC, Thomasson ED, McBee SM, Pauly NJ. Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak — West Virginia, 2018–2019 MMWR. 2021;70(8);269–72.
the results from this study highlight the potential financial cost jurisdictions might incur when ACIP recommendations for hepatitis A vaccination, especially among persons who use illicit drugs, are not followed…
Hong K, Zhou F, Tsai Y, Jatlaoui TC, Acosta AM, Dooling KL, et al. Decline in Receipt of Vaccines by Medicare Beneficiaries During the COVID-19 Pandemic — United States, 2020 MMWR. 2021;70(7);245–9.
Vaccination providers should emphasize the importance of routine adult vaccination to their patients and ensure the safe provision of vaccines to protect older adults from vaccine-preventable diseases during the ongoing COVID-19 pandemic…
Nguyen KH, Srivastav A, Razzaghi H, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020 MMWR. 2021;70(6);217–22.
Ensuring high and equitable vaccination coverage among all populations, including by addressing reasons for not intending to receive vaccination, is critical to prevent the spread of COVID-19 and bring an end to the pandemic…
Freedman MS, Ault K, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021 MMWR. 2021;70(6);193–6.
The 2021 adult immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and accompanying notes found on the CDC immunization schedule website…
Wodi AP, Ault K, Hunter P, McNally V, Szilagyi PG, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021 MMWR. 2021;70(6);189–92.
The 2021 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and notes found on the CDC immunization schedule website…
Gharpure R, Guo A, Bishnoi CK, Patel U, Gifford D, Tippins A, et al. Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021 MMWR. 2021;70(5);178–82.
Barriers to SNF staff member vaccination need to be overcome with continued development and implementation of focused communication and outreach strategies to improve vaccination coverage…
Painter EM, Ussery EN, Patel A, PharmD, Hughes MM, Zell ER, MStat, Moulia DL, et al. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021 MMWR. 2021;70(5);174–7.
As the vaccination program expands, it is critical to ensure efficient and equitable administration to persons in each successive vaccine priority category, especially those at highest risk for infection and severe health outcomes…

Top of Page

January 2021

CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 MMWR. 2021;70(4);125–9.
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020–January 10, 2021, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States and interim considerations for preparing for the potential management of anaphylaxis…
Seither R, McGill MT, Kriss JL, Mellerson JL, Loretan C, Driver K, et al. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2019–20 School Year MMWR. 2021;70(3);75–82.
This report provides data on overall national and median vaccination coverage for the state-required number of doses of DTaP, MMR, and varicella vaccine…
Choi MJ, Cossaboom CM, Whitesell AN, Dyal JW, Joyce A, Morgan RL, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 MMWR. 2021;70(RR-1);1–12.
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States…
CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 MMWR. 2021;70(2);46–51.
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14–23, 2020, in the United States…
Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(5152);1657–60.
In Phase 1b, COVID-19 vaccine should be offered to persons aged ≥75 years and non–health care frontline essential workers, and in Phase 1c, to persons aged 65–74 years, persons aged 16–64 years with high-risk medical conditions, and essential workers not included in Phase 1b…
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(51);1653–6.
On December 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19…

Archived MMWRs Related to Immunization News: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
Influenza-related MMWRs
Surveillance-related MMWRs
Immunization Works!
More news resources

Top of Page